Compare Aurora Cannabis Inc (ACB) vs Cigna Corp (CI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aurora Cannabis Inc vs Cigna Corp — how do they compare? Aurora Cannabis Inc trades at $2.66 (market cap $165.36M), while Cigna Corp trades at $289.55 (market cap $75.82B). The key difference: Cigna Corp is far larger — about 458.5× Aurora Cannabis Inc's market cap, and Cigna Corp pays a 2.18% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | CI | |
|---|---|---|
Market Cap | $165.36M | $75.82B |
Sector | Health | Health |
52-Week High | $6.23 | $312.00 |
52-Week Low | $2.67 | $244.41 |
Enterprise Value | $99.82M | $98.92B |
Dividend Yield | — | 2.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.
The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.
Cigna (CI) trades at $286.62, down 0.4% on the day, with a neutral technical signal. The stock shows strong fundamentals with a low P/E of 11.95 and consistent earnings beats, including Q1 2026 EPS of $7.79 versus $7.60 expected. Revenue grew to $273.85B in 2025, and the company is expanding into AI-driven healthcare services, as highlighted by recent news of Evernorth's Pharmacy Forward initiative (PRNewswire, 2026-07-01).
The outlook is positive given analyst consensus with a $338.91 price target and 73.68% buy ratings. Key risks include regulatory challenges, such as the Tennessee prescription access lawsuit (Reuters, 2026-06-12), and volatility in medical cost trends. The stock offers value with a dividend yield supported by a recent $1.56 payout, but investors should monitor execution in specialty pharmacy expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
